Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

Febuxostat is available as 40- and 80-mg tablets. The recommended starting dosage is 40 mg orally once daily. If serum uric acid concentrations are not less than 6 mg/dL after two weeks ...

Mean serum urate levels were 6.0 mg/dL among men and 4.8 mg/dL among ... An alternative XOI, Febuxostat, was launched in the US in 2009 with the hope of treating individuals with gout, however ...

Current first-line therapies like allopurinol and febuxostat can be very effective ... hit a target uric acid levels in the blood of 1.5 mg/dL or lower for at least 80% of the sixth months ...

A uric acid level of 6.8 mg/dl or higher means you have hyperuricemia ... Zyloprin (allopurinol), Uloric (febuxostat): These drugs are called xanthine oxidase inhibitors (XOIs). They reduce the body’s ...

MG’s new Cyber GTS electric coupe features a fixed roof and a 2+2 interior layout. The production version of the coupe will mirror the design of last year’s concept. The 2026 Cyberster gets ...

JSW MG Motor India has launched the E20-compliant 2025 Hector SUV, starting at Rs 13.99 lakh. Production began on March 31, 2025, aligning with new fuel regulations. MG is offering benefits up to ...

The U.S. Food and Drug Administration this week granted permission for the use of a new cancer drug from China despite ...

In this expert perspective, Manjot K. Gill, MD, discusses the potential FDA approval in 2025 of aflibercept 8 mg for the treatment of retinal vein occlusion.

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Merck will grow its U.S. manufacturing footprint with a $1 billion plant, making it the latest drugmaker to invest in the U.S ...

The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in ...